AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35078532 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 34521461 — intervention group
Group type: EXPERIMENTAL
Intervention: hUCB‐MSCs (1.0 × 10^7 cells/2 mL)
Number of subjects: 9
Study 34521461 — intervention group
Group type: EXPERIMENTAL
Intervention: hUCB‐MSCs (3.0 × 10^7 cells/2 mL)
Number of subjects: 9
Study 34521461 — intervention group
Group type: EXPERIMENTAL
Intervention: hUCB‐MSCs (1.0 × 10^7 cells/2 mL) and (3.0 × 10^7 cells/2 mL)
Number of subjects: 9
Study 34516051 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledentistry (education via Telegram application)
Number of subjects: 60
Study 34516051 — intervention group
Group type: COMPARATOR
Intervention: Conventional education (in-person education)
Number of subjects: 60
Study 34516051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Teledentistry and Conventional education)
Number of subjects: 60
Study 33022321 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-endorsed reminder letter
Number of subjects: 1200
Study 33022321 — intervention group
Group type: COMPARATOR
Intervention: Standard reminder letter
Number of subjects: 1200
Study 35687604 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Agility (RA)
Number of subjects: 14
Study 35687604 — intervention group
Group type: COMPARATOR
Intervention: Repeated Change-of-Direction (RCOD)
Number of subjects: 14
Study 35687604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue development in RA
Number of subjects: 14
Study 35687604 — intervention group
Group type: COMPARATOR
Intervention: Fatigue development in RCOD
Number of subjects: 14
Study 35687604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of perceived exertion (RPE) for RA
Number of subjects: 14
Study 35687604 — intervention group
Group type: COMPARATOR
Intervention: Ratings of perceived exertion (RPE) for RCOD
Number of subjects: 14
Study 35687604 — intervention group
Group type: EXPERIMENTAL
Intervention: Total RA times
Number of subjects: 14
Study 32524584 — intervention group
Group type: EXPERIMENTAL
Intervention: Early relapse after high-dose melphalan autologous stem cell transplant
Number of subjects: 0
Study 32524584 — intervention group
Group type: COMPARATOR
Intervention: Later relapsing patients after high-dose melphalan autologous stem cell transplant
Number of subjects: 0
Study 32808239 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 443
Study 32808239 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 443
Study 32808239 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 443
Study 36456007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided puncture
Number of subjects: 542
Study 36456007 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided puncture
Number of subjects: 542
Study 33380392 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block analgesia (TA)
Number of subjects: 90
Study 33380392 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 90
Study 33380392 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia (GA)
Number of subjects: 90
Study 36381163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bladder neck and supramontanal sparing TURP (Group 2)
Number of subjects: 90
Study 36381163 — intervention group
Group type: COMPARATOR
Intervention: Conventional TURP (Group 1)
Number of subjects: 90
Study 32473675 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 0
Study 32473675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33668309 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise
Number of subjects: 30
Study 33668309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 33032661 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted indoor residual spraying (TIRS) applied 1-2 months prior to the ABV season
Number of subjects: 4600
Study 33274466 — intervention group
Group type: EXPERIMENTAL
Intervention: MLT‐treated cryopreservation (10−9 M)
Number of subjects: 0
Study 33274466 — intervention group
Group type: COMPARATOR
Intervention: No‐MLT‐treated cryopreservation (NC)
Number of subjects: 0
Study 33148333 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta frequency EA (6 Hz)
Number of subjects: 66
Study 33148333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma frequency EA (40 Hz)
Number of subjects: 66
Study 33148333 — intervention group
Group type: COMPARATOR
Intervention: Sham EA (no current)
Number of subjects: 66
Study 33858190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin plus standard chemotherapy (GO + SC)
Number of subjects: 0
Study 33858190 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy alone (SC)
Number of subjects: 0
Study 35635622 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine consultation (TEL)
Number of subjects: 271
Study 35635622 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation (FTF)
Number of subjects: 271
Study 33786671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrimide 2% followed by methylene blue dye and aPDT
Number of subjects: 60
Study 33786671 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental solution (methylene blue dye with cetrimide) and aPDT
Number of subjects: 60
Study 33786671 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 33786671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2%
Number of subjects: 60
Study 33786671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrimide 2%
Number of subjects: 60
Study 33786671 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT alone
Number of subjects: 60
Study 32872501 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practice School Lunches (BPSL)
Number of subjects: 40
Study 32872501 — intervention group
Group type: COMPARATOR
Intervention: Typical School Lunches (TSL)
Number of subjects: 40
Study 35171918 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 63
Study 35171918 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 63
Study 34628241 — intervention group
Group type: EXPERIMENTAL
Intervention: Urox® (Bedtime Buddy®)
Number of subjects: 41
Study 34628241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 34843657 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 99
Study 34843657 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and caloric restriction
Number of subjects: 99
Study 34843657 — intervention group
Group type: COMPARATOR
Intervention: Usual activity
Number of subjects: 99
Study 33327963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Reality guidance system using Microsoft HoloLens
Number of subjects: 164
Study 33327963 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led instructions
Number of subjects: 164
Study 33327963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation
Number of subjects: 164
Study 33327963 — intervention group
Group type: COMPARATOR
Intervention: Quality of instructions (Control group)
Number of subjects: 164
Study 33327963 — intervention group
Group type: EXPERIMENTAL
Intervention: MR system usability (SUS score)
Number of subjects: 164
Study 33327963 — intervention group
Group type: EXPERIMENTAL
Intervention: NASA task load index (MR group)
Number of subjects: 164
Study 34939916 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention involving spiritual history taking by primary care physicians and advice on home remedies and regional programs for the elderly.
Number of subjects: 297
Study 34939916 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention for patients using home remedies before the trial.
Number of subjects: 297
Study 34939916 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention for patients who stated that spirituality played a major role in their lives.
Number of subjects: 297
Study 33712909 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneological outpatient treatment (hydrotherapy and peloidotherapy)
Number of subjects: 74
Study 33712909 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (Control)
Number of subjects: 74
Study 33116410 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of valsartan 80 mg capsules under fasting conditions
Number of subjects: 78
Study 33116410 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of valsartan 80 mg capsules under fed conditions
Number of subjects: 78
Study 33116410 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of valsartan 80 mg capsules
Number of subjects: 78
Study 36165675 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day prednisolone for 2 years
Number of subjects: 451
Study 36165675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 34488719 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention addressing interpreter engagement
Number of subjects: 55
Study 32386065 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand bupropion XL 300 mg
Number of subjects: 0
Study 32386065 — intervention group
Group type: COMPARATOR
Intervention: Generic bupropion XL 300 mg
Number of subjects: 0
Study 37164774 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) followed by curative chemo-radiotherapy (CTRT) or surgery and adjuvant (chemo)RT
Number of subjects: 35
Study 37164774 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT)
Number of subjects: 35
Study 33420736 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (VG)
Number of subjects: 378
Study 33420736 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 378
Study 32690330 — intervention group
Group type: COMPARATOR
Intervention: Monitoring recovery (Group A, n = 97)
Number of subjects: 207
Study 32690330 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring recovery + mutual aid association (Group B, n = 112)
Number of subjects: 207
Study 33324987 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 0
Study 32029248 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1660
Study 32029248 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1660
Study 32029248 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1660
Study 33949052 — intervention group
Group type: EXPERIMENTAL
Intervention: kcal labelling (standard labelling plus drink kilocalorie information)
Number of subjects: 1084
Study 33949052 — intervention group
Group type: EXPERIMENTAL
Intervention: kcal + PACE labelling (standard labelling and kilocalorie information, plus information on physical activity needed to compensate for drink calories)
Number of subjects: 1084
Study 33949052 — intervention group
Group type: COMPARATOR
Intervention: Control (standard alcohol labelling)
Number of subjects: 1084
Study 33620447 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based treatment via smartphone application
Number of subjects: 105
Study 34780107 — intervention group
Group type: EXPERIMENTAL
Intervention: Longstanding active exercise therapy (52 weeks)
Number of subjects: 430
Study 34780107 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 430
Study 34780107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 430
Study 32687582 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model based on pretreatment symptoms and electroencephalographic features
Number of subjects: 0
Study 35098177 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCoV mRNA vaccine (5 µg, 10 µg, 15 µg, 20 µg, 25 µg)
Number of subjects: 120
Study 35098177 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCoV mRNA vaccine
Number of subjects: 120
Study 35098177 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCoV mRNA vaccine (15 µg)
Number of subjects: 120
Study 35098177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33888418 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloons (PCB)
Number of subjects: 580
Study 33888418 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-coated balloons (SCB)
Number of subjects: 580
Study 33901759 — intervention group
Group type: EXPERIMENTAL
Intervention: iLookOut online child abuse identification and reporting training
Number of subjects: 1094
Study 33901759 — intervention group
Group type: COMPARATOR
Intervention: Standard mandated reporter training
Number of subjects: 1094
Study 34622504 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day vonoprazan-based triple therapy (7-VAC): vonoprazan 20 mg bid. pc., amoxicillin 1000 mg bid. pc., clarithromycin 500 mg bid. pc.
Number of subjects: 122
Study 34622504 — intervention group
Group type: COMPARATOR
Intervention: 14-day omeprazole-based triple therapy (14-OAC): omeprazole 20 mg bid. ac., amoxicillin 1000 mg bid. pc., clarithromycin 500 mg bid. pc.
Number of subjects: 122
Study 34866250 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Implants (SI)
Number of subjects: 40
Study 34866250 — intervention group
Group type: COMPARATOR
Intervention: Standard Length Implants (SLI) with MSFA
Number of subjects: 40
Study 32173228 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention consisting of oral presentation and distribution of fliers for 30 minutes.
Number of subjects: 1259
Study 32173228 — intervention group
Group type: COMPARATOR
Intervention: Control group received health talk on other aspects of neurology such as sleep, epilepsy, etc.
Number of subjects: 1259
Study 36357459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Face Test (CFT) intervention
Number of subjects: 28
Study 32629994 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured insoles of different heights
Number of subjects: 26
Study 32629994 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial arch
Number of subjects: 26
Study 32629994 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal feet)
Number of subjects: 26
Study 33992610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sensitivity pregnancy test
Number of subjects: 88
Study 33992610 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel pregnancy test
Number of subjects: 88
Study 32379244 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30
Study 32379244 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 34154321 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg i.m./month)
Number of subjects: 39
Study 34154321 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate
Number of subjects: 39
Study 34154321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 34154321 — intervention group
Group type: COMPARATOR
Intervention: Neridronate and Placebo
Number of subjects: 39
Study 32406553 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 41
Study 35733086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (4 ml of 2% lidocaine in the outer cuff)
Number of subjects: 98
Study 35733086 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (2 ng/ml maintained until extubation)
Number of subjects: 98
Study 33302570 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐hydroxyvitamin D3 (25OHD) 10 µg per day for 16 weeks
Number of subjects: 0
Study 33302570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35700209 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated WASH, MNCH, nutrition and ECD interventions
Number of subjects: 0
Study 35700209 — intervention group
Group type: COMPARATOR
Intervention: Control site
Number of subjects: 0
Study 35700209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention site
Number of subjects: 0
Study 33653118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezogabine (900 mg/day; N=21)
Number of subjects: 45
Study 33653118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=24)
Number of subjects: 45
Study 36274166 — intervention group
Group type: EXPERIMENTAL
Intervention: Plenum® Oss 3Dβ fit (alloplastic graft)
Number of subjects: 0
Study 36274166 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 0
Study 34186532 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHT) - 3 sessions per week for 8 weeks, consisting of 4 sets of isometric contractions for 2 min at 30% of maximum voluntary contraction.
Number of subjects: 53
Study 34186532 — intervention group
Group type: COMPARATOR
Intervention: Control group received a compression ball for sham training.
Number of subjects: 53
Study 33689525 — intervention group
Group type: EXPERIMENTAL
Intervention: lacto‐ovo‐vegetarian diet (LOV‐D)
Number of subjects: 75
Study 33338441 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody seropositivity in the general population
Number of subjects: 8902
Study 33338441 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody seropositivity in the high-risk population
Number of subjects: 8902
Study 33073938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg every night for three months
Number of subjects: 42
Study 33073938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 42
Study 33122288 — intervention group
Group type: EXPERIMENTAL
Intervention: KIM-1
Number of subjects: 894
Study 33122288 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR-1
Number of subjects: 894
Study 33122288 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR-2
Number of subjects: 894
Study 33122288 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 894
Study 33122288 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR
Number of subjects: 894
Study 33122288 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL-40
Number of subjects: 894
Study 32878112 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated walking program for 6 months
Number of subjects: 70
Study 32878112 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 35216750 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop system (Diabeloop DBL4K)
Number of subjects: 21
Study 35216750 — intervention group
Group type: COMPARATOR
Intervention: Open-loop system (sensor-augmented pump therapy)
Number of subjects: 21
Study 32386001 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal directed sedation (EGDS) with continuous intravenous infusion of dexmedetomidine (initial dose of 0.2 μg×kg‐1×min‐1) for 72 hours
Number of subjects: 105
Study 32386001 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal directed sedation (EGDS)
Number of subjects: 105
Study 32386001 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation (STD) with intravenous bolus of propofol
Number of subjects: 105
Study 32386001 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation (STD)
Number of subjects: 105
Study 34383143 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) at-home bleaching
Number of subjects: 40
Study 34071401 — intervention group
Group type: EXPERIMENTAL
Intervention: Video emphasizing sexual impotence (n = 60)
Number of subjects: 269
Study 34071401 — intervention group
Group type: EXPERIMENTAL
Intervention: Video emphasizing cognitive impairment (n = 72)
Number of subjects: 269
Study 34071401 — intervention group
Group type: EXPERIMENTAL
Intervention: Video emphasizing long-term effects (cancer, cardiovascular disease, n = 68)
Number of subjects: 269
Study 32520132 — intervention group
Group type: EXPERIMENTAL
Intervention: Expository lectures
Number of subjects: 90
Study 32520132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity simulator model
Number of subjects: 90
Study 32520132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulator model
Number of subjects: 90
Study 32732777 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training with blood flow restriction (STBFR)
Number of subjects: 19
Study 32732777 — intervention group
Group type: COMPARATOR
Intervention: Normal soccer training (ST)
Number of subjects: 19
Study 32967799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezacaftor/ivacaftor
Number of subjects: 67
Study 32967799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 32967799 — intervention group
Group type: COMPARATOR
Intervention: Ivacaftor
Number of subjects: 67
Study 32223108 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills (QLP), 6 g tid for 6 months
Number of subjects: 168
Study 32223108 — intervention group
Group type: COMPARATOR
Intervention: Placebo control, 6 g tid for 6 months
Number of subjects: 168
Study 36458443 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (T) of apixaban 2.5 mg under fasting conditions
Number of subjects: 64
Study 36458443 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (T) of apixaban 2.5 mg under fed conditions
Number of subjects: 64
Study 36458443 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (R) of apixaban 2.5 mg under fasting conditions
Number of subjects: 64
Study 36458443 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (R) of apixaban 2.5 mg under fed conditions
Number of subjects: 64
Study 34409637 — intervention group
Group type: EXPERIMENTAL
Intervention: Causally associated genes identified through PMR-Egger analysis.
Number of subjects: 552
Study 34409637 — intervention group
Group type: EXPERIMENTAL
Intervention: Causally associated genes identified through Bayesian co-localization analysis.
Number of subjects: 552
Study 34409637 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis.
Number of subjects: 552
Study 32506498 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 40
Study 32506498 — intervention group
Group type: COMPARATOR
Intervention: Sterile island dressing
Number of subjects: 40